<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Phenytoin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00252</strong>&#160; (APRD00241)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00252/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00252/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00252.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00252.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00252.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00252.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00252.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00252">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>5,5-Diphenyl-imidazolidine-2,4-dione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5,5-diphenylimidazolidine-2,4-dione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5,5-diphenyltetrahydro-1H-2,4-imidazoledione	</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Fenitoina</td><td>Spanish</td><td>INN</td></tr><tr><td>Phenytoine</td><td>French</td><td>INN</td></tr><tr><td>Phenytoinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Phenytoin Sodium </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000139/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000139/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: FJPYVLNWWICYDW-UHFFFAOYSA-M</li>
              <li>Monoisotopic Mass: 274.071822281</li>
              <li>Average Mass: 274.2498</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000139">DBSALT000139</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Dilantin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Dilantin-125</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Epanutin</td><td> Pfizer</td></tr><tr><td>Eptoin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Phenytek</td><td>Mylan Laboratories</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Dilantin W Phenobarbital 15mg</td><td>Phenobarbital + Phenytoin Sodium</td></tr><tr><td>Dilantin W Phenobarbital 30mg Cap</td><td>Phenobarbital + Phenytoin Sodium</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anticonvulsants">Anticonvulsants</a></li>
<li><a href="/mesh/voltage-gated-sodium-channel-blockers">Voltage-Gated Sodium Channel Blockers</a></li></ul></td></tr><tr><th>CAS number</th><td>57-41-0</td></tr><tr><th>Weight</th><td>Average: 252.268<br>Monoisotopic: 252.089877638</td></tr><tr><th>Chemical Formula</th><td>C<sub>15</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>CXOFVDLJLONNDW-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">5,5-diphenylimidazolidine-2,4-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00252.gif?1265922771">show</a>(9.46 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Azolidines</td></tr><tr><th>Subclass</th><td>Imidazolidines</td></tr><tr><th>Direct parent</th><td>Phenylhydantoins</td></tr><tr><th>Alternative parents</th><td>Diphenylmethanes; Phenylimidazolidines; Ureides; N-unsubstituted Carboxylic Acid Imides; Secondary Carboxylic Acid Amides; Polyamines; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>phenylimidazolidine; ureide; benzene; carboxylic acid imide, n-unsubstituted; secondary carboxylic acid amide; carboxamide group; carboxylic acid derivative; polyamine; carboxylic acid; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.</td></tr><tr><th>Pharmacodynamics</th><td>Phenytoin is an antiepileptic drug which can be useful in the treatment of epilepsy. The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of tonic-clonic (grand mal) seizures. Phenytoin acts to dampen the unwanted, runaway brain activity seen in seizure by reducing electrical conductance among brain cells. It lacks the sedation effects associated with phenobarbital. There are some indications that phenytoin has other effects, including anxiety control and mood stabilization, although it has never been approved for those purposes by the FDA. Phenytoin is primarily metabolized by CYP2C9.</td></tr><tr><th>Mechanism of action</th><td>Phenytoin acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. By promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of post-tetanic potentiation at synapses. Loss of post-tetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas.</td></tr><tr><th>Absorption</th><td>Bioavailability 70-100% oral, 24.4% for rectal and intravenous administration. Rapid rate of absorption with peak blood concentration expected in 1&#189; to 3 hours.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Highly protein bound, 90%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Primarily hepatic. The majority of the dose (up to 90%) is metabolized to 5-(4'-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). This metabolite undergoes further glucuronidation and is excreted into the urine. CYP2C19 and CYP2C9 catalyze the aforementioned reaction. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Phenytoin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0003533" target="_blank">Cytochrome P450 2E1</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0003336" target="_blank">Cytochrome P450 2A6</a></li>
<li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0004787" target="_blank">Epoxide hydrolase 1</a></li></ul></td><td><a href="/metabolites/DBMET00058">3',4'-Dihydrodiol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/58">Details</a></td></tr><tr><td>Phenytoin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00059">3'-HPPH</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/59">Details</a></td></tr><tr><td>Phenytoin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET00284">4'-HPPH</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/285">Details</a></td></tr><tr><td>Phenytoin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00988">Phenytoin arene-oxide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1011">Details</a></td></tr><tr><td>Phenytoin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00989">Phenytoin catechol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1012">Details</a></td></tr><tr><td>Phenytoin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00992">Phenytoin quinone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1015">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00989">Phenytoin catechol</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002089" target="_blank">Catechol O-methyltransferase</a></li></ul></td><td><a href="/metabolites/DBMET00991">Phenytoin methylcatechol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1174">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00988">Phenytoin arene-oxide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0003336" target="_blank">Cytochrome P450 2A6</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0003533" target="_blank">Cytochrome P450 2E1</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0004787" target="_blank">Epoxide hydrolase 1</a></li></ul></td><td><a href="/metabolites/DBMET00990">Phenytoin dihydrodiol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1177">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00988">Phenytoin arene-oxide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00888">Hydroxyphenytoin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1178">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00888">Hydroxyphenytoin</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00989">Phenytoin catechol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1180">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00989">Phenytoin catechol</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0001184" target="_blank">NAD(P)H dehydrogenase [quinone] 1</a></li></ul></td><td><a href="/metabolites/DBMET00992">Phenytoin quinone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1181">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00888">Hydroxyphenytoin</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003541" target="_blank">UDP-glucuronosyltransferase 1-1</a></li>
<li><a href="/biodb/bio_entities/BE0003544" target="_blank">UDP-glucuronosyltransferase 1-4</a></li>
<li><a href="/biodb/bio_entities/BE0004694" target="_blank">UDP-glucuronosyltransferase 1-6</a></li>
<li><a href="/biodb/bio_entities/BE0003538" target="_blank">UDP-glucuronosyltransferase 1-9</a></li></ul></td><td><a href="/metabolites/DBMET00889">Hydroxyphenytoin-O-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1183">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00059">3'-HPPH</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET01149">3',4'-diHPPH</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1278">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00284">4'-HPPH</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET01149">3',4'-diHPPH</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1279">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Most of the drug is excreted in the bile as inactive metabolites which are then reabsorbed from the intestinal tract and excreted in the urine. Urinary excretion of phenytoin and its metabolites occurs partly with glomerular filtration but, more importantly, by tubular secretion.</td></tr><tr><th>Half life</th><td>22 hours (range of 7 to 42 hours)</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral, mouse: LD<sub>50</sub> = 150 mg/kg; Oral, rat: LD<sub>50</sub> = 1635 mg/kg. Symptoms of overdose include coma, difficulty in pronouncing words correctly, involuntary eye movement, lack of muscle coordination, low blood pressure, nausea, sluggishness, slurred speech, tremors, and vomiting.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Fosphenytoin (Antiarrhythmic) Action Pathway</td><td>Drug action</td></tr><tr><td>Phenytoin (Antiarrhythmic) Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00327?highlight%5Bcompounds%5D%5B%5D=DB00252&amp;highlight%5Bproteins%5D%5B%5D=DB00252">SMP00327</a></td></tr><tr><td>Fosphenytoin (Antiarrhythmic) Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00618?highlight%5Bcompounds%5D%5B%5D=DB00252&amp;highlight%5Bproteins%5D%5B%5D=DB00252">SMP00618</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Cytochrome P450 2C9<br>Gene symbol: CYP2C9<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P11712" target="_blank">P11712 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1057910" target="_blank">rs1057910 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2C9*1</td><td>C Allele</td><td>Poor drug metabolizer, lower dose requirements</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/15805193" target="_blank" title="Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB: Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5507-12. Epub 2005 Apr 1.">15805193 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Multidrug resistance protein 1<br>Gene symbol: ABCB1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P08183" target="_blank">P08183 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1045642" target="_blank">rs1045642 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>MDR1*T</td><td>T Allele (C3435T)</td><td>Increased phenytoin effects due to higher plasma phenytoin levels</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/11908757" target="_blank" title='# Kerb R, Aynacioglu AS, Brockmoller J, Schlagenhaufer R, Bauer S, Szekeres T, Hamwi A, Fritzer-Szekeres M, Baumgartner C, Ongen HZ, Guzelbey P, Roots I, Brinkmann U: The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 2001;1(3):204-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11908757'>11908757 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9909</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.976</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5593</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8782</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.987</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8995</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.733</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8911</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7591</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8304</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.935</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8994</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.855
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.992
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1567 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9793
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8916
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Parke davis div warner lambert co</li>
<li>Actavis mid atlantic llc</li>
<li>Taro pharmaceutical industries ltd</li>
<li>Vistapharm inc</li>
<li>Wockhardt eu operations (swiss) ag</li>
<li>Pfizer pharmaceuticals ltd</li>
<li>Lannett co inc</li>
<li>Amneal pharmaceuticals ny llc</li>
<li>Barr laboratories inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Pliva inc</li>
<li>Sun pharmaceutical industries ltd</li>
<li>Wockhardt ltd</li>
<li>Wockhardt usa inc</li>
<li>Watson laboratories inc</li>
<li>Pharmeral inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Parke davis pharmaceutical research div warner lambert co</li>
<li>App pharmaceuticals llc</li>
<li>Baxter healthcare corp</li>
<li>Hikma farmaceutica (portugal) sa</li>
<li>Hospira inc</li>
<li>Marsam pharmaceuticals llc</li>
<li>Pharmaforce inc</li>
<li>Smith and nephew solopak div smith and nephew</li>
<li>Solopak medical products inc</li>
<li>Warner chilcott div warner lambert co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.actavis.com">Actavis Group</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.amneal.com">Amneal Pharmaceuticals</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bilcare.com">Bilcare Inc.</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li>C.O. Truxton Inc.</li>
<li><a href="http://www.caraco.com">Caraco Pharmaceutical Labs</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Carlisle Laboratories Inc.</li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Coupler Enterprises Inc.</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.giv.com">General Injectables and Vaccines Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.hikma.com">Hikma Pharmaceuticals</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.jhppharma.com">JHP Pharmaceuticals LLC</a></li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li>Pharmaceutical Packaging Center</li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prasco.com">Prasco Labs</a></li>
<li><a href="http://www.precisiondose.com">Precision Dose Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.sunpharma.com">Sun Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.vistapharm.com">Vistapharm Inc.</a></li>
<li><a href="http://ir.wcrx.com">Warner Chilcott Co. Inc.</a></li>
<li>Warner Lambert Company LLC</li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li>
<li>Xactdose Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>30 mg, 100 mg, 200 mg, 300 mg</td></tr><tr><td>Injection, solution</td><td>Oral</td><td>50 mg/mL</td></tr><tr><td>Tablet</td><td>Oral</td><td>125 mg/5 mL</td></tr><tr><td>Tablet, chewable</td><td>Oral</td><td>50 mg </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB05812">Abiraterone</a></td><td>Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Increased hydantoin levels and risk of bleeding</td></tr><tr><td><a href="/drugs/DB05773">ado-trastuzumab emtansine</a></td><td>Avoid combination with phenytoin and other strong CYP3A4 inducers due to the likely increase in metabolism of ado-trastuzumab emtansine to its active component, DM1.</td></tr><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>Phenytoin may increase the metabolism of alprazolam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Decreased effect of both products</td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Amiodarone may increase the therapeutic and adverse effects of phenytoin.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Increased hydantoin levels and risk of bleeding</td></tr><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>The CYP3A4 inducer, phenytoin, may decrease the effect of aprepitant.</td></tr><tr><td><a href="/drugs/DB06216">Asenapine</a></td><td>Phenytoin is a CYP1A2 inducer and may increase metabolism of asenapine. </td></tr><tr><td><a href="/drugs/DB00732">Atracurium</a></td><td>Phenytoin decreases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB06626">Axitinib</a></td><td>Avoid combination with phenytoin and other strong, moderate, or weak CYP3A4 inducers due to the likely decreased levels of axitinib.


</td></tr><tr><td><a href="/drugs/DB00443">Betamethasone</a></td><td>The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, betamethasone.</td></tr><tr><td><a href="/drugs/DB00290">Bleomycin</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB08873">Boceprevir</a></td><td>Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB06772">Cabazitaxel</a></td><td>Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. </td></tr><tr><td><a href="/drugs/DB08907">Canagliflozin</a></td><td>Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily. </td></tr><tr><td><a href="/drugs/DB01101">Capecitabine</a></td><td>Capecitabine increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00958">Carboplatin</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00262">Carmustine</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00446">Chloramphenicol</a></td><td>Increases phenytoin, modifies chloramphenicol</td></tr><tr><td><a href="/drugs/DB00475">Chlordiazepoxide</a></td><td>Phenytoin may increase the metabolism of chlordiazepoxide via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00269">Chlorotrianisene</a></td><td>The enzyme inducer, phenytoin, decreases the effect of the hormone agent, chlorotrianisene.</td></tr><tr><td><a href="/drugs/DB01114">Chlorphenamine</a></td><td>The antihistamine increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine may increase the therapeutic effect of phenytoin.</td></tr><tr><td><a href="/drugs/DB00537">Ciprofloxacin</a></td><td>Ciprofloxacin may decrease the therapeutic effect of phenytoin.</td></tr><tr><td><a href="/drugs/DB00515">Cisplatin</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Clarithromycin may increase the therapeutic and adverse effects of phenytoin.</td></tr><tr><td><a href="/drugs/DB00882">Clomifene</a></td><td>The enzyme inducer, phenytoin, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00628">Clorazepate</a></td><td>Phenytoin may increase the metabolism of clorazepate via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Phenytoin may decrease the effect of clozapine.</td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>Colesevelam may decrease the serum concentration of Phenytoin. Phenytoin should be administered at least 4 hours prior to colesevelam. </td></tr><tr><td><a href="/drugs/DB00286">Conjugated Estrogens</a></td><td>The enzyme inducer, phenytoin, decreases the effect of the hormone agent, conjugated estrogens.</td></tr><tr><td><a href="/drugs/DB01380">Cortisone acetate</a></td><td>The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, cortisone acetate.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>The hydantoin decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB08912">Dabrafenib</a></td><td>Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01254">Dasatinib</a></td><td>Phenytoin may decrease the serum level and efficacy of dasatinib.</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>The anticonvulsant, phenytoin, decreases the effect of delavirdine.</td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, dexamethasone.</td></tr><tr><td><a href="/drugs/DB00829">Diazepam</a></td><td>Phenytoin may increase the metabolism of diazepam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB01119">Diazoxide</a></td><td>Diazoxide decreases the efficacy of phenytoin. </td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Increased hydantoin levels and risk of bleeding</td></tr><tr><td><a href="/drugs/DB00255">Diethylstilbestrol</a></td><td>The enzyme inducer, phenytoin, decreases the effect of the hormone agent, diethylstilbestrol.</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>The hydantoin decreases the effect of disopyramide</td></tr><tr><td><a href="/drugs/DB00822">Disulfiram</a></td><td>Disulfiram may increase the therapeutic and adverse effects of phenytoin.</td></tr><tr><td><a href="/drugs/DB00988">Dopamine</a></td><td>Risk of severe hypotension</td></tr><tr><td><a href="/drugs/DB01135">Doxacurium chloride</a></td><td>Phenytoin decreases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>The anticonvulsant, phenytoin, may decrease the effect of doxycycline.</td></tr><tr><td><a href="/drugs/DB00651">Dyphylline</a></td><td>Decreased effect of both products</td></tr><tr><td><a href="/drugs/DB00783">Estradiol</a></td><td>The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estradiol.</td></tr><tr><td><a href="/drugs/DB08866">Estradiol valerate/Dienogest</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB04573">Estriol</a></td><td>The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estriol.</td></tr><tr><td><a href="/drugs/DB00655">Estrone</a></td><td>The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estrone.</td></tr><tr><td><a href="/drugs/DB04574">Estropipate</a></td><td>The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estropipate.</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Etravirine, when used concomitantly with phenytoin, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.</td></tr><tr><td><a href="/drugs/DB04953">Ezogabine</a></td><td>Ezogabine increases the clearance of phenytoin (30%). The mechanism of this interaction is unknown. </td></tr><tr><td><a href="/drugs/DB00949">Felbamate</a></td><td>Increased phenytoin levels and decreased felbamate levels</td></tr><tr><td><a href="/drugs/DB01023">Felodipine</a></td><td>The hydantoin decreases the effect of felodipine</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole may increase the therapeutic and adverse effects of phenytoin.</td></tr><tr><td><a href="/drugs/DB00687">Fludrocortisone</a></td><td>The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00544">Fluorouracil</a></td><td>Fluorouracil increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Fluoxetine increases the effect of phenytoin</td></tr><tr><td><a href="/drugs/DB00690">Flurazepam</a></td><td>Phenytoin may increase the metabolism of flurazepam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Fluvoxamine may increase the therapeutic effect of phenytoin.</td></tr><tr><td><a href="/drugs/DB00158">Folic Acid</a></td><td>Folic acid may decrease the levels of phenytoin.</td></tr><tr><td><a href="/drugs/DB00695">Furosemide</a></td><td>The hydantoin decreases the effect of furosemide</td></tr><tr><td><a href="/drugs/DB00996">Gabapentin</a></td><td>Gabapentin may increase the therapeutic and adverse effects of phenytoin.</td></tr><tr><td><a href="/drugs/DB00317">Gefitinib</a></td><td>The CYP3A4 inducer, phenytoin, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, hydrocortisone.</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>The hydantoin decreases the levels of imatinib</td></tr><tr><td><a href="/drugs/DB00762">Irinotecan</a></td><td>The hydantoin decreases the effect of irinotecan</td></tr><tr><td><a href="/drugs/DB00951">Isoniazid</a></td><td>Isoniazid increases the effect of phenytoin in 20% of patients</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Phenytoin decreases the effect of itraconazole</td></tr><tr><td><a href="/drugs/DB08820">Ivacaftor</a></td><td>Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01235">L-DOPA</a></td><td>The hydantoin decreases the effect of levodopa</td></tr><tr><td><a href="/drugs/DB00555">Lamotrigine</a></td><td>Phenytoin may reduce levels of lamotrigine</td></tr><tr><td><a href="/drugs/DB00367">Levonorgestrel</a></td><td>Phenytoin decreases the contraceptive effect</td></tr><tr><td><a href="/drugs/DB01601">Lopinavir</a></td><td>Levels of both drugs are affected</td></tr><tr><td><a href="/drugs/DB00643">Mebendazole</a></td><td>The hydantoin decreases the efficiency of mebendazole</td></tr><tr><td><a href="/drugs/DB00603">Medroxyprogesterone Acetate</a></td><td>The enzyme inducer, phenytoin, may decrease the effect of medroxyprogesterone.</td></tr><tr><td><a href="/drugs/DB00351">Megestrol acetate</a></td><td>The enzyme inducer, phenytoin, may decrease the effect of megestrol.</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>The hydantoin decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00553">Methoxsalen</a></td><td>The hydantoin decreases the effect of psoralene</td></tr><tr><td><a href="/drugs/DB00959">Methylprednisolone</a></td><td>The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, methylprednisolone.</td></tr><tr><td><a href="/drugs/DB01336">Metocurine</a></td><td>Phenytoin decreases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB01011">Metyrapone</a></td><td>The combination renders the test invalid</td></tr><tr><td><a href="/drugs/DB00379">Mexiletine</a></td><td>The hydantoin decreases the effect of mexiletine</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Phenytoin may increase the metabolism of midazolam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00370">Mirtazapine</a></td><td>The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects</td></tr><tr><td><a href="/drugs/DB01226">Mivacurium</a></td><td>Phenytoin decreases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB00401">Nisoldipine</a></td><td>Phenytoin decreases the efficiency of nisoldipine</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>Omeprazole increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00776">Oxcarbazepine</a></td><td>Oxcarbazepine increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Decreased effect of both products</td></tr><tr><td><a href="/drugs/DB03585">Oxyphenbutazone</a></td><td>The NSAID, oxphenbutazone, may increase the therapeutic and adverse effects of phenytoin.</td></tr><tr><td><a href="/drugs/DB01337">Pancuronium</a></td><td>Phenytoin decreases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB01384">Paramethasone</a></td><td>The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, paramethasone.</td></tr><tr><td><a href="/drugs/DB08883">Perampanel</a></td><td>Avoid combination with phenytoin or other strong CYP3A4 inducers due to the likely decrease of perampanel concentration. If the combination must be used, an increase in perampanel dose is necessary.
 </td></tr><tr><td><a href="/drugs/DB00812">Phenylbutazone</a></td><td>The NSAID, phenylbutazone, may increase the therapeutic and adverse effects of phenytoin.</td></tr><tr><td><a href="/drugs/DB08901">Ponatinib</a></td><td>Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB08901">Ponatinib</a></td><td>Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>Modifications of drug levels for both agents</td></tr><tr><td><a href="/drugs/DB01058">Praziquantel</a></td><td>Markedly lower praziquantel levels</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisolone.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisone.</td></tr><tr><td><a href="/drugs/DB01224">Quetiapine</a></td><td>Phenytoin decreases the effect of quetiapine</td></tr><tr><td><a href="/drugs/DB04575">Quinestrol</a></td><td>The enzyme inducer, phenytoin, decreases the effect of the hormone agent, quinestrol.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>The anticonvulsant, phenytoin, decreases the effect of quinidine.</td></tr><tr><td><a href="/drugs/DB08896">Regorafenib</a></td><td>Strong CYP3A4 inducers may decrease levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the therapeutic and adverse effects of phenytoin.</td></tr><tr><td><a href="/drugs/DB08864">Rilpivirine</a></td><td>Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. </td></tr><tr><td><a href="/drugs/DB06201">Rufinamide</a></td><td>Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide.</td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Sertraline increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00877">Sirolimus</a></td><td>The hydantoin decreases sirolimus levels</td></tr><tr><td><a href="/drugs/DB00364">Sucralfate</a></td><td>Sucralfate decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00359">Sulfadiazine</a></td><td>The sulfonamide increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00576">Sulfamethizole</a></td><td>The sulfonamide increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB01268">Sunitinib</a></td><td>Possible decrease in sunitinib levels</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Phenytoin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Phenytoin therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Phenytoin may decrease the plasma concentration of Telithromycin by increasing its metabolism. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Phenytoin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Decreased effect of both products</td></tr><tr><td><a href="/drugs/DB04572">Thiotepa</a></td><td>Possible increase in thiotepa levels</td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Ticlopidine may decrease the metabolism and clearance of phenytoin. Consider alternate therapy or monitor for adverse/toxic effects of phenytoin if ticlopidine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Phenytoin decreases the concentration of Tipranavir. Monitor for decreased Tipranavir efficacy.</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Avoid combination with phenytoin and other strong CYP3A4 inducers due to the potential decrease in tofacitinib serum levels.

</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Phenytoin. Consider alternate therapy or monitor for changes in Phenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB06212">Tolvaptan</a></td><td>Phenytoin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. </td></tr><tr><td><a href="/drugs/DB00273">Topiramate</a></td><td>Increased phenytoin/decreased topiramate</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Phenytoin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inducer, Phenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenytoin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>The strong CYP2C8 inducer, Phenytoin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Phenytoin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00620">Triamcinolone</a></td><td>The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, triamcinolone.</td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>Phenytoin may increase the metabolism of triazolam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00440">Trimethoprim</a></td><td>Trimethoprim increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB04571">Trioxsalen</a></td><td>The hydantoin decreases the effect of psoralene</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Phenytoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01199">Tubocurarine</a></td><td>Phenytoin decreases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB08867">Ulipristal</a></td><td>Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. </td></tr><tr><td><a href="/drugs/DB05294">Vandetanib</a></td><td>Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  </td></tr><tr><td><a href="/drugs/DB01339">Vecuronium</a></td><td>Phenytoin decreases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB08881">Vemurafenib</a></td><td>Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Verapamil may increase the serum concentration of Phenytoin by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Phenytoin if Verapamil is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01080">Vigabatrin</a></td><td>Vigabatrin reduces plasma levels of phenytoin by 16-20% which may be due to induction of CYP2C. Consider dosage adjustment. </td></tr><tr><td><a href="/drugs/DB00570">Vinblastine</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole may increase the serum concentration of phenytoin by decreasing its metabolism. Phenytoin may increase the serum concentration of voriconazole by increasing its metabolism. Consider alternate antifungal therapy or monitor for voriconazole therapy failure and phenytoin toxicity.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Warfarin may increase the serum concentration of phenytoin possibly by competing for CYP2C9 metabolism. Phenytoin may increase the anticoagulant effect of warfarin. Monitor phenytoin levels, prothrombin time, and therapeutic and adverse effects of both agents during concomitant therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.</li>
<li>Take with food to increase bioavailability and reduce irritation.</li></ul></td></tr></tbody></table>